Divis Laboratories
Divis Laboratories
Shareholder Return: 3-year, Sales Growth: 3-year CAGR, Return On Equity: 3-year average
At a Glance
-
Shareholder Return108%
-
Sales Growth21%
-
Return on Equity28 %
Why Super 50
The active pharmaceutical ingredients (API) as well as the contract research and manufacturing (CRM) businesses have both generated growth for the Hyderabad-based pharmaceutical major in the recent past. Divis is supplementing its two FDA-inspected manufacturing facilities (in Hyderabad and Visakhapatnam) with another facility in Kakinada, Andhra Pradesh, with an investment of Rs 550 crore.
